Patients who are 'Poor Metabolizers' of CYP2D6 are at increased risk of therapeutic failure when treated with which prodrug?
Show answer and explanation
Correct answer: Codeine
Codeine is a prodrug that must be converted by CYP2D6 into its active metabolite, morphine, to provide analgesia. Poor metabolizers lack sufficient enzyme activity to make this conversion, resulting in little to no pain relief.
Keep practicing
More Pharmacogenomics questions
- The presence of the HLA-B*15:02 allele is a strong predictor of Stevens-Johnson Syndrome (SJS) in patients taking which medication?
- A polymorphism in the VKORC1 gene primarily affects which pharmacokinetic or pharmacodynamic process of Warfarin?
- Testing for the HLA-B*57:01 allele is mandatory before prescribing which antiretroviral drug to prevent hypersensitivity reactions?
- Which enzyme deficiency puts patients at high risk for severe, life-threatening toxicity when treated with 5-Fluorouracil (5-FU) or Capecit…
- TPMT genotyping is used to guide the dosing of which class of drugs?
- Which CYP450 polymorphism is most relevant for the activation of the antiplatelet drug Clopidogrel?